Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Royalty Pharma (RPRXN) Stock Price & Analysis

1 Followers

RPRXN Stock Chart & Stats

MX$1,213.52MX$0.00(0.00%)
At close:
Mex$1KMex$1.1KMex$1.2KAug 17Aug 25Oct 27
Day’s Range
MXN 1,213.52 - MXN 1,250.00
52-Week Range
MXN 666.41 - MXN 1,250.00
Previous Close
MXN 1,213.52
Volume
0
Average Volume (3M)
137
Market Cap
MXN 719.49B
Enterprise Value
MXN 42.30B
Total Cash (Recent Filing)
MXN 836.99M
Total Debt (Recent Filing)
MXN 8.96B
Price to Earnings (P/E)
27.6
Beta
0.15
Next Earnings
Nov 04, 2026 (Est.)
EPS Estimate
22.25
Next Dividend Ex-Date
N/A
Dividend Yield
1.33%

Bulls Say, Bears Say

Bulls Say

Strong Cash Generation

Royalty Pharma converts a high proportion of its earnings into cash, with operating cash flow improving and free cash flow matching it in the provided data. This supports debt service, acquisitions, shareholder returns, and continued investment without relying solely on external financing.

High And Resilient Profitability

Exceptionally high operating margins are consistent with the royalty model, which avoids direct clinical development, manufacturing, and commercialization costs. The persistence of elevated margins across annual periods indicates durable earnings quality and meaningful operating leverage.

Expanding Royalty Pipeline

A much larger development-stage pipeline broadens future royalty opportunities and reduces reliance on the current portfolio alone. Management also cites a roughly 90% historical success rate for investments progressing to approval, supporting the potential for durable portfolio growth.

Bears Say

Meaningful Leverage

The rising debt burden reduces financial flexibility if royalty receipts or acquisition activity weaken. Although cash generation and investment-grade debt provide support, leverage increases the importance of maintaining portfolio performance and disciplined capital allocation over the coming periods.

Product And Policy Revenue Headwinds

Loss of exclusivity, biosimilar competition, and possible policy effects can pressure receipts from affected products and weigh on portfolio growth. These are identifiable commercial and regulatory changes, so their impact may persist beyond a single quarter rather than being temporary volatility.

Dependence On Development Outcomes

Development-stage assets can expand future royalties, but their value depends on clinical and regulatory outcomes that remain uncertain. Until pivotal results are available, expected returns and portfolio growth from these investments may differ materially from current projections.

Royalty Pharma News

RPRXN FAQ

What was Royalty Pharma’s price range in the past 12 months?
Royalty Pharma lowest stock price was Mex$666.41 and its highest was Mex$1250.00 in the past 12 months.
What is Royalty Pharma’s market cap?
Royalty Pharma’s market cap is Mex$719.49B.
When is Royalty Pharma’s upcoming earnings report date?
Royalty Pharma’s next earnings report is estimated for Nov 04, 2026 (not yet confirmed), which is today.
How were Royalty Pharma’s earnings last quarter?
Royalty Pharma released its earnings results on Aug 05, 2026. The company reported Mex$24.884 earnings per share for the quarter, beating the consensus estimate of Mex$23.98 by Mex$0.904.
Is Royalty Pharma overvalued?
According to Wall Street analysts Royalty Pharma’s price is currently Undervalued.
Does Royalty Pharma pay dividends?
Royalty Pharma does not currently pay dividends.
What is Royalty Pharma’s EPS estimate?
Royalty Pharma’s EPS estimate is 22.25.
How many shares outstanding does Royalty Pharma have?
Royalty Pharma has 446,619,200 shares outstanding.
What happened to Royalty Pharma’s price movement after its last earnings report?
Royalty Pharma reported an EPS of Mex$24.884 in its last earnings report, beating expectations of Mex$23.98. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Royalty Pharma?
Hedge funds hold Royalty Pharma shares: hedge funds decreased their holdings by 249.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology